TELA Bio, Inc. (TELA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TELA Bio, Inc., a Delaware corporation, on March 17, 2026. The Company is an emerging growth company with its principal executive offices in Malvern, Pennsylvania. Its common stock trades on the Nasdaq Global Market under the symbol "TELA".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a regulatory listing deficiency regarding the Company's stock price.
Material Changes and Events
On March 17, 2026, the Company received a deficiency letter from the Nasdaq Listing Qualifications Department. The notification states that for the last 30 consecutive business days, the closing bid price of the Company's common stock has been below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5450(a)(1). The deficiency letter has no immediate effect on the listing, and trading continues under the symbol "TELA".
Outlook, Risks, and Management Commentary
The Company has been granted an initial 180-calendar-day period, until September 14, 2026, to regain compliance. Compliance can be achieved if the bid price closes at $1.00 or more for a minimum of 10 consecutive business days before the deadline. If the Company fails to regain compliance by September 14, 2026, it may be afforded a second 180-day period, contingent upon transferring to The Nasdaq Capital Market and meeting its initial listing standards (excluding the minimum bid price requirement). Failure to cure the deficiency within the second period could result in delisting. The Company may appeal a delisting determination to a Nasdaq Hearings Panel, though success is not assured. Management intends to actively monitor the stock price and consider available options to resolve the deficiency.
Key Facts for Investor Verification
- Deficiency Trigger: Stock price closed below $1.00 for 30 consecutive business days ending March 17, 2026.
- Compliance Deadline: September 14, 2026, to restore the bid price to $1.00 for 10 consecutive days.
- Delisting Risk: Potential delisting from Nasdaq if compliance is not achieved within the initial or potential second 180-day period.
- Market Transfer: A second compliance period requires transferring to The Nasdaq Capital Market and meeting its market value of publicly held shares requirement.
- Appeal Process: The Company retains the right to appeal a delisting determination, with no guarantee of success.